Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

(RTTNews) - Amgen Inc. (AMGN) Thursday announced positive data from the Phase 3 MINT study of Uplizna in adults with generalized myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune ...

Results from the company’s double-blind, placebo-controlled Mint study (NCT04524273) showed 72.3% of acetylcholine receptor autoantibody-positive (AChR+) gMG patients dosed with Uplizna saw a ...

72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3.